Canada's Largest Biotech IPO

On June 22, 2000, Neurochem Inc. of Montreal closed its initial public offering of 3,878,787 common shares at a price of $8.25 per share for a total offering of $32 million ($36.8 million if an over-allotment option granted to the underwriters is exercised), making it the biggest Canadian biotech IPO.

Neurochem is a biopharmaceutical company focused on the development of therapeutic treatments for a number of major diseases characterized by the presence of toxic deposits of amyloid protein. The diseases currently targeted by Neurochem include Alzheimer’s disease, certain Systemic Amyloidosis disorders, Hemorrhagic Stroke and Diabetes Type II (the most common form of diabetes). Neurochem’s core drug development efforts focus on the rational drug design and synthesis of small organic molecules that inhibit the formation, deposition and toxicity of the amyloid fibrils implicated as the underlying cause of these diseases.

The Montreal office of Goodman Phillips & Vineberg acted for Neurochem Inc. and were led by Richard Cherney, Justin D. Vineberg, Jodi Lackman and Michael Kandev (corporate and securities), Claude Jodoin (tax). The Montreal office of Ogilvy Renault represented the underwriters with a team that included Clemens Mayr (corporate and securities), Alain Côté (tax) and Natalie Brown (corporate and securities).


Alain Côté Richard D. Cherney Justin D. Vineberg Clemens Mayr Jodi A. Lackman Claude E. Jodoin


Davies Ward Phillips & Vineberg LLP Norton Rose Fulbright Canada LLP